In June 2019, the U.S. FDA approved selinexor (Xpovio) in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma.  Myeloma patients had to have been treated with at least four prior therapies.  In November 2020, the results of the BOSTON study were published which demonstrated the benefits of using selinexor earlier in the treatment pathway.  The study outcomes led the U.S. FDA to approve selinexor for adults...

Two new research projects co-funded through a partnership between America’s The Leukemia & Lymphoma Society (LLS), Snowdome Foundation and Leukaemia Foundation will focus on...

Professor Pimanda is incredibly curious. His observations around why cells behave in certain ways and respond variably to stimuli led him down a cell...